论文部分内容阅读
目的:探讨干扰素介导的跨膜蛋白1(Interferon-induced transmembrane protein 1,IFITM1)基因在卵巢上皮性癌中表达的相关性及其意义。方法:应用Western blotting检测正常卵巢、卵巢良性肿瘤、卵巢交界性肿瘤和卵巢上皮性癌组织中IFITM1蛋白表达。免疫组织化学检测12例正常卵巢、21例卵巢良性肿瘤、18例卵巢交界性肿瘤和85例卵巢上皮性癌组织中IFITM1的蛋白表达,同时分析IFITM1表达状况与临床病理因素之间的相关性。结果:Western blotting显示卵巢上皮性癌和卵巢交界性肿瘤中IFITM1表达水平明显高于正常卵巢组织和卵巢良性肿瘤。免疫组化显示在正常卵巢组织中IFITM1阳性表达率为41.7%(5/12),在卵巢良性肿瘤组织中71.4%(15/21),在卵巢交界性肿瘤组织中为72.2%(13/18),在卵巢上皮性癌中为77.6%(66/85),IFITM1蛋白表达强度在正常卵巢、良性卵巢肿瘤、交界性卵巢肿瘤、上皮性卵巢癌间的比较有统计学意义(P<0.05)。IFITM1蛋白表达与病理类型、肿瘤分化程度、肿瘤FIGO分期有关(P<0.05),与淋巴结转移、腹水无明显相关性。化疗敏感组和耐药组的IFITM1表达强度间差异有统计学意义(P<0.05)。结论:IFITM1在正常卵巢、卵巢良性肿瘤、卵巢交界性肿瘤和卵巢上皮性癌组织中的表达依次升高,并与卵巢癌以铂类为基础的化疗耐药性产生有相关性,为进一步研究IFITM1在卵巢癌诊治及化疗中的应用前景提供依据。
Objective: To investigate the correlation between Interferon-induced transmembrane protein 1 (IFITM1) gene expression in epithelial ovarian cancer and its significance. Methods: The expression of IFITM1 in normal ovary, benign ovarian tumor, borderline ovarian tumor and ovarian epithelial carcinoma was detected by Western blotting. Immunohistochemistry was used to detect the protein expression of IFITM1 in 12 cases of normal ovary, 21 cases of ovarian benign tumor, 18 cases of ovarian borderline tumor and 85 cases of epithelial ovarian cancer. Meanwhile, the correlation between the expression of IFITM1 and clinicopathological factors was also analyzed. Results: Western blotting showed that the expression of IFITM1 in epithelial ovarian cancer and borderline ovarian tumors was significantly higher than that in normal ovarian tissues and benign ovarian tumors. Immunohistochemistry showed that the positive rate of IFITM1 was 41.7% (5/12) in normal ovarian tissues, 71.4% (15/21) in benign ovarian tumors and 72.2% (13/18) in borderline ovarian tumor ), 77.6% (66/85) in epithelial ovarian cancer. The expression of IFITM1 protein in normal ovary, benign ovarian tumor, borderline ovarian tumor and epithelial ovarian cancer was statistically significant (P <0.05) . The expression of IFITM1 protein was correlated with the pathological type, tumor differentiation degree and FIGO stage (P <0.05), but not with lymph node metastasis and ascites. There was significant difference in the expression intensity of IFITM1 between chemotherapy-sensitive group and drug-resistant group (P <0.05). CONCLUSION: The expression of IFITM1 in normal ovary, benign ovarian tumor, borderline ovarian tumor and epithelial ovarian cancer is in turn increased, which is correlated with chemoresistance of ovarian cancer based on platinum-based chemotherapy. For further study IFITM1 in the diagnosis and treatment of ovarian cancer and chemotherapy application prospects.